FDA Alerts

The FDA has approved a new treatment option for the prophylaxis of venous thromboembolism in hospitalized patients.

After a multicenter trial demonstrated its efficacy, the US Food and Drug Administration approved a subcutaneous option for the treatment of hereditary angioedema.

The US Food and Drug Administration has approved the first treatment for a genetic mutation of non-small cell lung cancer, and also approved the diagnostic test for determining multiple genetic mutations...

The US Food and Drug Administration has approved a combination intravenous treatment for follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

The FDA has approved a new option for the treatment of adolescents and adults with ADHD.

A new drug found to be effective against gram-positive and gram-negative pathogens, including MRSA, has been approved by the FDA.

The US Food and Drug Administration has approved an immunotherapy with the first CD38-directed antibody to be approved in any country.

The FDA has expanded the approval of a drug to include the treatment of adults with lower limb spasticity.

A new epipen will be available soon for patients with severe emergency allergic reactions. For more information on the drug, read more.

After careful consideration, the FDA has requested that a particular opioid analgesic be removed from the market.